|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/19/2005 5:12:53 PM
COSTA MESA, Calif.--(BUSINESS WIRE)--March 1, 2005--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has completed its acquisition of Xcel Pharmaceuticals, following the early termination by the U.S. Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.
Timothy C. Tyson, Valeant's President and Chief Executive Officer, said, "Our teams moved rapidly to complete this transaction. The acquisition of Xcel is expected to expand our business in the United States with $60 million in revenues from in-market products, significantly accelerate the growth of our neurology franchise with a highly-specialized sales force, and add retigabine, a novel Phase 3 compound with significant market potential, to our pipeline."
|
|
|
|
|
|
|
|
|
|
|